Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1991 Oct;35(10):2053–2056. doi: 10.1128/aac.35.10.2053

Influence of albumin on itraconazole and ketoconazole antifungal activity: results of a dynamic in vitro study.

M Schäfer-Korting 1, H C Korting 1, F Amann 1, R Peuser 1, A Lukacs 1
PMCID: PMC245325  PMID: 1662022

Abstract

The relevance of intense protein binding to the antifungal activity of azole compounds is still a matter of debate. The influence of albumin on the antimicrobial activity of ketoconazole and itraconazole, which exhibit very strong plasma protein binding (99 and 99.8%), was evaluated in vitro. Candida albicans was exposed to continuously changing azole concentrations corresponding to drug levels in serum following an oral dose of 200 mg. Total as well as free drug levels in serum were simulated. The incubation medium was free of proteins or contained 4% human serum albumin. Itraconazole levels reflecting free drug concentrations in humans did not reduce the growth rate of C. albicans, as compared with controls (difference in the log CFU per milliliter at 12 h, 0.03 +/- 0.09), whereas total drug levels were as active in the presence of 4% albumin (mean difference, -0.61) as in its absence (-0.75). The same was true for ketoconazole, except that free drug levels were also active (-1.21 versus -1.39 for total drug levels). This result was due to the higher ketoconazole levels in humans. Thus, in terms of routine susceptibility testing, in vitro total drug levels can be considered relevant.

Full text

PDF
2053

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barre J., Didey F., Delion F., Tillement J. P. Problems in therapeutic drug monitoring: free drug level monitoring. Ther Drug Monit. 1988;10(2):133–143. doi: 10.1097/00007691-198802000-00002. [DOI] [PubMed] [Google Scholar]
  2. Bergeron M. G., Brusch J. L., Barza M., Weinstein L. Bactericidal activity and pharmacology of cefazolin. Antimicrob Agents Chemother. 1973 Oct;4(4):396–401. doi: 10.1128/aac.4.4.396. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Carver P. L., Nightingale C. H., Quintiliani R. Pharmacokinetics and pharmacodynamics of total and unbound cefoxitin and cefotetan in healthy volunteers. J Antimicrob Chemother. 1989 Jan;23(1):99–106. doi: 10.1093/jac/23.1.99. [DOI] [PubMed] [Google Scholar]
  4. Eichmann A., Weidmann G., Havas L. One-dose treatment of acute uncomplicated gonorrhoea of male patients with ceftriaxone Ro 13-9904, a new parenteral cephalosporin. A dose-range finding pilot study using doses of 500, 250, 125 and 50 mg respectively, in descending order. Chemotherapy. 1981;27 (Suppl 1):62–69. doi: 10.1159/000238031. [DOI] [PubMed] [Google Scholar]
  5. Galgiant J. N., Stevens D. A. Turbidimetric studies of growth inhibition of yeasts with three drugs: inquiry into inoculum-dependent susceptibility testing, time of onset of drug effect, and implications for current and newer methods. Antimicrob Agents Chemother. 1978 Feb;13(2):249–254. doi: 10.1128/aac.13.2.249. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Grasso S., Meinardi G., de Carneri I., Tamassia V. New in vitro model to study the effect of antibiotic concentration and rate of elimination on antibacterial activity. Antimicrob Agents Chemother. 1978 Apr;13(4):570–576. doi: 10.1128/aac.13.4.570. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Heel R. C., Brogden R. N., Carmine A., Morley P. A., Speight T. M., Avery G. S. Ketoconazole: a review of its therapeutic efficacy in superficial and systemic fungal infections. Drugs. 1982 Jan-Feb;23(1-2):1–36. doi: 10.2165/00003495-198223010-00001. [DOI] [PubMed] [Google Scholar]
  8. Korting H. C., Lukacs A., Schäfer-Korting M., Heykants J., Behrendt H. Skin blister fluid levels of ketoconazole during repetitive administration in healthy man. Mycoses. 1989 Jan;32(1):39–45. doi: 10.1111/j.1439-0507.1989.tb02168.x. [DOI] [PubMed] [Google Scholar]
  9. Korting H. C., Ollert M., Georgii A., Fröschl M. In vitro susceptibilities and biotypes of Candida albicans isolates from the oral cavities of patients infected with human immunodeficiency virus. J Clin Microbiol. 1988 Dec;26(12):2626–2631. doi: 10.1128/jcm.26.12.2626-2631.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Korting H. C., Ollert M., Lukacs A., Schäfer-Korting M. Can the clinical efficacy of different antibiotic dosage regimens in gonorrhoea be predicted from the gonocidal effect of the corresponding plasma level profiles simulated in vitro? Acta Derm Venereol. 1987;67(2):154–159. [PubMed] [Google Scholar]
  11. Korting H. C., Schlaf-Maier U., Schäfer-Korting M. Antimikrobielle Effekte des in vitro simulierten Ketoconazol-Kantharidinblasenflüssigkeitsspiegel-Profils bei Candida albicans. Mykosen. 1986 Jul;29(7):297–305. [PubMed] [Google Scholar]
  12. Kunin C. M., Craig W. A., Kornguth M., Monson R. Influence of binding on the pharmacologic activity of antibiotics. Ann N Y Acad Sci. 1973 Nov 26;226:214–224. doi: 10.1111/j.1749-6632.1973.tb20483.x. [DOI] [PubMed] [Google Scholar]
  13. Lee K. L., Buckley H. R., Campbell C. C. An amino acid liquid synthetic medium for the development of mycelial and yeast forms of Candida Albicans. Sabouraudia. 1975 Jul;13(2):148–153. doi: 10.1080/00362177585190271. [DOI] [PubMed] [Google Scholar]
  14. McIntyre K. A., Galgiani J. N. In vitro susceptibilities of yeasts to a new antifungal triazole, SCH 39304: effects of test conditions and relation to in vivo efficacy. Antimicrob Agents Chemother. 1989 Jul;33(7):1095–1100. doi: 10.1128/aac.33.7.1095. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Merrikin D. J., Briant J., Rolinson G. N. Effect of protein binding on antibiotic activity in vivo. J Antimicrob Chemother. 1983 Mar;11(3):233–238. doi: 10.1093/jac/11.3.233. [DOI] [PubMed] [Google Scholar]
  16. Rolinson G. N., Sutherland R. The binding of antibiotics to serum proteins. Br J Pharmacol Chemother. 1965 Dec;25(3):638–650. doi: 10.1111/j.1476-5381.1965.tb01788.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Salkin I. F., Land G. A., Hurd N. J., Goldson P. R., McGinnis M. R. Evaluation of YeastIdent and Uni-Yeast-Tek yeast identification systems. J Clin Microbiol. 1987 Apr;25(4):624–627. doi: 10.1128/jcm.25.4.624-627.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Schäfer-Korting M., Korting H. C., Dorn M., Mutschler E. Ketoconazole concentrations in human skin blister fluid and plasma. Int J Clin Pharmacol Ther Toxicol. 1984 Jul;22(7):371–374. [PubMed] [Google Scholar]
  19. Schäfer-Korting M., Korting H. C., Lukacs A., Heykants J., Behrendt H. Levels of itraconazole in skin blister fluid after a single oral dose and during repetitive administration. J Am Acad Dermatol. 1990 Feb;22(2 Pt 1):211–215. doi: 10.1016/0190-9622(90)70026-e. [DOI] [PubMed] [Google Scholar]
  20. Selwyn S. Rational choice of penicillins and cephalosporins based on parallel in-vitro and in-vivo tests. Lancet. 1976 Sep 18;2(7986):616–619. doi: 10.1016/s0140-6736(76)90679-6. [DOI] [PubMed] [Google Scholar]
  21. Wise R. The clinical relevance of protein binding and tissue concentrations in antimicrobial therapy. Clin Pharmacokinet. 1986 Nov-Dec;11(6):470–482. doi: 10.2165/00003088-198611060-00004. [DOI] [PubMed] [Google Scholar]
  22. von Hattingberg H. M., Brockmeier D., Kreuter G. A rotating iterative procedure (RIP) for estimating hybrid constants in multi-compartment analysis on desk computers. Eur J Clin Pharmacol. 1977;11(5):381–388. doi: 10.1007/BF00566536. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES